6533b85afe1ef96bd12b95f9

RESEARCH PRODUCT

Role of Cytoreductive surgery in recurrent ovarian cancer

Giovanni ScambiaGiuseppe VizzielliBarbara CostantiniValerio GallottaCristiano RossittoFrancesco FanfaniAnna FagottiFederico Romano

subject

Secondary cytoreductionOncologymedicine.medical_specialtyendocrine system diseaseshypertermic intraoperative peritoneal chemotherapyGynecologic oncology; HIPEC; Hyperthermic intraoperative peritoneal chemotherapy; Recurrent ovarian cancer; Secondary cytoreductionGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreductionDiseaseGynecologic oncologyHyperthermic intraoperative peritoneal chemotherapyInternal medicinemedicinePharmacology (medical)Cause of deathHIPECbusiness.industrySystemic chemotherapyCombination chemotherapyGeneral Medicinemedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaGynecologic oncologyGinecologic oncology Hipec recurrent ovarian cancer secondary cytoreduction; hypertermic intraoperative peritoneal chemotherapyRecurrent Ovarian CancerRecurrent ovarian cancerbusinessOvarian cancerCytoreductive surgery

description

Ovarian cancer is the leading cause of death from gynecologic malignancy in western countries, primarily because over 60% of patients with ovarian cancer will experience disease recurrence. Primary cytoreductive surgery and combination chemotherapy are the cornerstones of the initial treatment for epithelial ovarian cancer. The management of recurrent ovarian cancer is less clear than that of primary disease. The management of recurrent ovarian cancer is largely based on systemic chemotherapy, with surgery being offered only in selected individuals. Despite this, the benefits of surgery has been shown in a meta-analysis by Bristow et al. where the survival is influenced by the completeness of cytoreduction. Therefore, epithelial ovarian cancer can be accepted as a chronic disease that consists of multiple recurrence and retreatments such as further surgeries and chemotherapies. The clinical applicability of this secondary surgery remains a controversial topic. Therefore, a trial on secondary surgery for r...

yearjournalcountryeditionlanguage
2010-01-01
http://hdl.handle.net/10447/98483